- Ultragenyx (NASDAQ:RARE +3.1%) announces that it plans to file a U.S. marketing application by mid-2019 seeking approval for UX007 for the treatment of patients with long-chain fatty acid oxidation disorders. The application will be supported with Phase 2 data.
- UX007 is a purified pharmaceutical-grade form of a triglyceride compound called triheptanoin that provides patients with medium-length odd-chain fatty acids which increase the intermediate substrates in the Krebs cycle, a key energy-generating process, which produces new glucose.
- Previously: Ultragenyx up 3% premarket on FDA sign-off early filing of NDA for UX007 (Aug. 29)
Ultragenyx on go with U.S. marketing application for UX007 for mid-2019; shares up 3%
Recommended For You
More Trending News
About RARE Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
RARE | - | - |
Ultragenyx Pharmaceutical Inc. |